165 related articles for article (PubMed ID: 19907500)
21. Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma.
Lamfers ML; Gianni D; Tung CH; Idema S; Schagen FH; Carette JE; Quax PH; Van Beusechem VW; Vandertop WP; Dirven CM; Chiocca EA; Gerritsen WR
Cancer Res; 2005 Oct; 65(20):9398-405. PubMed ID: 16230403
[TBL] [Abstract][Full Text] [Related]
22. Double E1B 19 kDa- and E1B 55 kDa-deleted oncolytic adenovirus in combination with radiotherapy elicits an enhanced anti-tumor effect.
Kim J; Kim PH; Yoo JY; Yoon AR; Choi HJ; Seong J; Kim IW; Kim JH; Yun CO
Gene Ther; 2009 Sep; 16(9):1111-21. PubMed ID: 19494843
[TBL] [Abstract][Full Text] [Related]
23. VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment.
Qiao J; Moreno J; Sanchez-Perez L; Kottke T; Thompson J; Caruso M; Diaz RM; Vile R
Gene Ther; 2006 Oct; 13(20):1457-70. PubMed ID: 16724095
[TBL] [Abstract][Full Text] [Related]
24. Potent antitumor effect of neurotensin receptor-targeted oncolytic adenovirus co-expressing decorin and Wnt antagonist in an orthotopic pancreatic tumor model.
Na Y; Choi JW; Kasala D; Hong J; Oh E; Li Y; Jung SJ; Kim SW; Yun CO
J Control Release; 2015 Dec; 220(Pt B):766-82. PubMed ID: 26471393
[TBL] [Abstract][Full Text] [Related]
25. Use of protamine to augment adenovirus-mediated cancer gene therapy.
Lanuti M; Kouri CE; Force S; Chang M; Amin K; Xu K; Blair I; Kaiser L; Albelda S
Gene Ther; 1999 Sep; 6(9):1600-10. PubMed ID: 10490770
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of E1B gene-attenuated replicating adenoviruses for cancer gene therapy.
Kim J; Cho JY; Kim JH; Jung KC; Yun CO
Cancer Gene Ther; 2002 Sep; 9(9):725-36. PubMed ID: 12189522
[TBL] [Abstract][Full Text] [Related]
27. Oncolytic Ad co-expressing decorin and Wnt decoy receptor overcomes chemoresistance of desmoplastic tumor through degradation of ECM and inhibition of EMT.
Li Y; Hong J; Jung BK; Oh E; Yun CO
Cancer Lett; 2019 Sep; 459():15-29. PubMed ID: 31150821
[TBL] [Abstract][Full Text] [Related]
28. Selective intratumoral amplification of an antiangiogenic vector by an oncolytic virus produces enhanced antivascular and anti-tumor efficacy.
Thorne SH; Tam BY; Kirn DH; Contag CH; Kuo CJ
Mol Ther; 2006 May; 13(5):938-46. PubMed ID: 16469543
[TBL] [Abstract][Full Text] [Related]
29. ADP-overexpressing adenovirus elicits enhanced cytopathic effect by induction of apoptosis.
Yun CO; Kim E; Koo T; Kim H; Lee YS; Kim JH
Cancer Gene Ther; 2005 Jan; 12(1):61-71. PubMed ID: 15375379
[TBL] [Abstract][Full Text] [Related]
30. Targeting gene-virotherapy of cancer and its prosperity.
Liu XY
Cell Res; 2006 Nov; 16(11):879-86. PubMed ID: 17102812
[TBL] [Abstract][Full Text] [Related]
31. Synergy between expression of fusogenic membrane proteins, chemotherapy and facultative virotherapy in colorectal cancer.
Hoffmann D; Bangen JM; Bayer W; Wildner O
Gene Ther; 2006 Nov; 13(21):1534-44. PubMed ID: 16791286
[TBL] [Abstract][Full Text] [Related]
32. Suppression of tumorigenicity by adenovirus-mediated gene transfer of decorin.
Reed CC; Gauldie J; Iozzo RV
Oncogene; 2002 May; 21(23):3688-95. PubMed ID: 12032837
[TBL] [Abstract][Full Text] [Related]
33. A hypoxia- and {alpha}-fetoprotein-dependent oncolytic adenovirus exhibits specific killing of hepatocellular carcinomas.
Kwon OJ; Kim PH; Huyn S; Wu L; Kim M; Yun CO
Clin Cancer Res; 2010 Dec; 16(24):6071-82. PubMed ID: 21169258
[TBL] [Abstract][Full Text] [Related]
34. Decorin suppresses bone metastasis in a breast cancer cell line.
Araki K; Wakabayashi H; Shintani K; Morikawa J; Matsumine A; Kusuzaki K; Sudo A; Uchida A
Oncology; 2009; 77(2):92-9. PubMed ID: 19590249
[TBL] [Abstract][Full Text] [Related]
35. In vivo imaging of adenovirus transduction and enhanced therapeutic efficacy of combination therapy with conditionally replicating adenovirus and adenovirus-p27.
Lee CT; Lee YJ; Kwon SY; Lee J; Kim KI; Park KH; Kang JH; Yoo CG; Kim YW; Han SK; Chung JK; Shim YS; Curiel DT; Carbone DP
Cancer Res; 2006 Jan; 66(1):372-7. PubMed ID: 16397251
[TBL] [Abstract][Full Text] [Related]
36. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.
Zhang Q; Chen G; Peng L; Wang X; Yang Y; Liu C; Shi W; Su C; Wu H; Liu X; Wu M; Qian Q
Clin Cancer Res; 2006 Nov; 12(21):6523-31. PubMed ID: 17085667
[TBL] [Abstract][Full Text] [Related]
37. An armed oncolytic adenovirus ZD55-IL-24 combined with ADM or DDP demonstrated enhanced antitumor effect in lung cancer.
Zhong S; Yu D; Wang Y; Qiu S; Wu S; Liu XY
Acta Oncol; 2010; 49(1):91-9. PubMed ID: 19734998
[TBL] [Abstract][Full Text] [Related]
38. Potent antitumor effect of tumor microenvironment-targeted oncolytic adenovirus against desmoplastic pancreatic cancer.
Li Y; Hong J; Oh JE; Yoon AR; Yun CO
Int J Cancer; 2018 Jan; 142(2):392-413. PubMed ID: 28929492
[TBL] [Abstract][Full Text] [Related]
39. Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression.
Kuppuswamy M; Spencer JF; Doronin K; Tollefson AE; Wold WS; Toth K
Gene Ther; 2005 Nov; 12(22):1608-17. PubMed ID: 16034456
[TBL] [Abstract][Full Text] [Related]
40. Adenovirus-based virotherapy enabled by cellular YB-1 expression in vitro and in vivo.
Rognoni E; Widmaier M; Haczek C; Mantwill K; Holzmüller R; Gansbacher B; Kolk A; Schuster T; Schmid RM; Saur D; Kaszubiak A; Lage H; Holm PS
Cancer Gene Ther; 2009 Oct; 16(10):753-63. PubMed ID: 19363467
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]